Pharmacogenetic Perspectives in Improving Pharmacokinetic Profiles for Efficient Bioequivalence Trials with Highly Variable Drugs
DOI:
https://doi.org/10.29070/zzfa6m26Keywords:
Bioequivalence, pharmacogenetics, highly variable drugs, pharmacokinetics, genetic polymorphisms, drug metabolism, adaptive trial design, inter-subject variability, pharmacokinetic profilingAbstract
Highly variable drugs (HVDs), characterized by an intra-subject coefficient of variation (CV%) exceeding 30%, pose significant challenges in bioequivalence (BE) trials. Their variability stems from complex pharmacokinetics (PK), influenced by genetic polymorphisms in drug-metabolizing enzymes, transporters, and other pathways. These challenges often lead to larger sample sizes and higher costs. Pharmacogenetics, the study of genetic factors influencing drug response, offers a solution by stratifying participants based on genetic profiles to minimize variability. This paper discusses the role of pharmacogenetics in addressing these challenges, emphasizing its potential to optimize trial design, reduce sample sizes, and improve efficiency. Keywords include bioequivalence, pharmacogenetics, highly variable drugs, pharmacokinetics, genetic polymorphisms, and adaptive trial design.
References
Zhang, W., & Reynolds, K. S. (2019). Role of pharmacogenetics in bioequivalence trials for highly variable drugs. Journal of Clinical Pharmacology, 59(8), 945-955.
European Medicines Agency (EMA). (2010). Guideline on the investigation of bioequivalence.
Rodrigues, A. D. (2021). Drug-drug interactions and pharmacogenetics in pharmacokinetics variability. Drug Metabolism and Disposition, 49(3), 279-296.
Cavallari, L. H., et al. (2020). Role of pharmacogenomics in precision medicine: Applications in BE trials. Pharmacogenomics Journal, 20(6), 477-491.
This work is licensed under a 